DXM + MDMA

https://dxm-atlas.org/en/interactions/mdma/

Compare

Key points for this combination

Serotonin-related effects and autonomic stress. In a human study, MDMA markedly changed DXM concentrations and metabolism. These findings are the basis for high confidence in direct evidence (D) [3].

General concepts in this text

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

Serotonin

A neurotransmitter: a substance that carries a chemical signal from a nerve cell.

There are different serotonin receptors in the brain and other parts of the body. The response to the signal depends on the receptor and its location.

Sources: Serotonin

Drug metabolism

Chemical transformation of a medicine in the body.

The resulting substances are metabolites. Transformation can reduce or increase pharmacological activity.

Sources: Drug metabolism

How well is this understood?

Mechanism confidence: high

Confidence in the mechanism: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Confidence in human DXM data: high

Confidence in direct human evidence involving DXM: high

M is confidence in the interaction mechanism. D is confidence in direct human findings involving DXM. Each is rated high, medium or low. D concerns what was tested under specific conditions, such as a change in drug concentration or an effect that was not found. Confidence in these findings, the PHI hazard rating and publication count are separate characteristics.

Method
Measurements of drug concentration or metabolism.

How to read ratings and study limits

How do the substances interact?

Can the amount reaching the body change?

In a controlled study, 15 healthy men took MDMA by mouth, followed by DXM as a metabolic probe.

Mechanism: 2D6 — CYP2D6 metabolism
ⓘ

CYP2D6

One of the CYP enzymes involved in processing drugs.

Inhibition means reducing enzyme activity; it can change the processing of drugs.

Sources: CYP2D6
  1. Total DXM exposure (AUC) → DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3]. Finding below: Total DXM exposure (AUC)
  2. Recovery of CYP2D6 activity → The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours. Finding below: Recovery of CYP2D6 activity

How can the effects add up?

Mechanism: REL — Monoamine release
ⓘ

Neurotransmitter release

Movement of neurotransmitter molecules from a nerve ending into the space between cells.

During release a neurotransmitter leaves a nerve ending; during reuptake it returns into a cell.

Sources: Neurotransmitter release
Mechanism: SYM — Cardiovascular and thermal stress
ⓘ

Autonomic nervous system

The part of the nervous system that regulates the heart, internal organs and glands without conscious control of each response.

The sympathetic division is part of this system. In a response to threat it can increase heart rate and sweating.

Sources: Autonomic nervous system

What is known about this combination?

Details from the source

The reported recovery half-life of 46.6 hours is a monoexponential model estimate. The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3]. See the MDMA study details.

Recovery half-life

A measure of how quickly enzyme activity recovers, calculated from changes in an activity marker over time.

In an exponential model, the recovery half-life is the time for a falling marker to halve. The marker can be the ratio of a test substance to its breakdown product.

Sources: Recovery half-life

In the glossary

What remains unknown?

The measurements concern DXM and its metabolites. The fold increase depends on exposure and can differ at other doses. The abstract reports CYP2D6 recovery after approximately 10 days. The full text estimates a recovery half-life of 46.6 hours from a monoexponential fit to a urinary metabolic-ratio marker and describes a remaining departure from baseline at the 10-day observation [3]. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.

The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].

The study did not determine the duration of MDMA intoxication or a safe waiting interval for an individual [3].

Sources

Check the review’s wording

Serotonergic and autonomic stress; marked alteration of DXM PK; *High D concerns PK [3]

Combination row in the review: 2D6 — CYP2D6 metabolism; REL — Monoamine release; SYM — Cardiovascular and thermal stress

Evidence and sources

Research publication

[3] · The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans · 2008

Total DXM exposure (AUC)

What was found?

DXM Cmax and AUC increased approximately tenfold, while DXO measures decreased [3].

Study context

In a controlled study, 15 healthy men took MDMA by mouth, followed by DXM as a metabolic probe.

Recovery of CYP2D6 activity

What was found?

The abstract reports CYP2D6 recovery after approximately 10 days and a recovery half-life of 46.6 hours.

In the full text, the half-life is estimated from urine tests: the authors used a monoexponential model to describe how the ratio of a substance to its metabolite changed over time.

At day 10, this ratio still differed from baseline. The authors discuss that result and the limitations of the recovery models.

The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].

CYP2D6 recovery — abstract

Approximately 10 days

CYP2D6 recovery half-life — model estimate

46.6 hours

What limits this finding?

The measurements concern DXM and its metabolites. The fold increase depends on exposure and can differ at other doses. The abstract reports CYP2D6 recovery after approximately 10 days. The full text estimates a recovery half-life of 46.6 hours from a monoexponential fit to a urinary metabolic-ratio marker and describes a remaining departure from baseline at the 10-day observation [3]. The study did not measure poisoning rates during combined recreational use or establish an individual safe waiting interval.

The authors note that the estimate appears to underestimate the time to recovery. They question the validity of a longer biphasic-model estimate because of variability in the data and insufficient data points over time [3].

The study did not determine the duration of MDMA intoxication or a safe waiting interval for an individual [3].

Scientific review: MAOIs and MDMA

Related entries

Reference

Open the source and related combinations →